| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab176429-100μg |
100μg |
期货  |
| |
| Ab176429-1mg |
1mg |
现货 |
| |
| Ab176429-5mg |
5mg |
现货 |
| |
| Ab176429-10mg |
10mg |
期货 |
|
| 产品名称 | Inotuzumab (anti-CD22), CD22 结合剂的结合剂 |
|---|---|
| 别名 | 奥英妥珠单抗 | 伊诺珠单抗（抗 CD22） |
| 英文别名 | B cell receptor CD22 precursor antibody | B lymphocyte cell adhesion molecule antibody | B-cell receptor CD22 antibody | B-lymphocyte cell adhesion molecule antibody | BL CAM antibody | BL-CAM antibody | BLCAM antibody | CD 22 antibody | CD22 antibody | C |
| 规格或纯度 | 无载体, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | CD22 |
| 种属反应性 | 人(Human),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 结合剂 |
| 作用机制 | CD22 结合剂的结合剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 27.0 kDa (Light Chain) & 50.2 kDa (Heavy Chain), under reducing conditions; 171.7 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1660159-36-3 |
| 分子类型 | 抗体 |
Inotuzumab (anti-CD22) (Ab176429) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD22 with Inotuzumab (anti-CD22) (Ab176429) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156150).
Inotuzumab (anti-CD22) (Ab176429) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling CD22 (red) with Inotuzumab (anti-CD22) (Ab176429) conjugated with biotin and detected with SA-PE (rp156150). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Inotuzumab (anti-CD22) (Ab176429) - Flow Cytometry
Flow Cytometry analysis of Ramos cells labelling CD22 (red) with Inotuzumab (anti-CD22) (Ab176429). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Inotuzumab (anti-CD22) (Ab176429) - SEC
The purity of Inotuzumab (anti-CD22) (Ab176429) is more than 95% verified by HPLC.
Inotuzumab (anti-CD22) (Ab176429) - ELISA
Immobilized Recombinant Human Siglec-2/CD22 Protein (rp169575) at 1.0 μg/mL can bind Inotuzumab (anti-CD22) (Ab176429) with the EC₅₀ of 20.07 ng/mL.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ23F1001500 |
分析证书 | 23-11-02 | Ab176429 |
| ZJ23F1001499 |
分析证书 | 23-11-02 | Ab176429 |
¥669.90
¥519.90
¥669.90
¥339.90
¥399.90
¥499.90
¥599.90
¥559.90
¥599.90
| 1. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.. J Clin Oncol, 30 (15): (1822-8). [PMID:22355053] [10.1021/op500134e] |
| 2. Kreitman RJ, Pastan I. (2011) Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.. Clin Cancer Res, 17 (20): (6398-405). [PMID:22003067] [10.1021/op500134e] |
| 3. Leonard JP, Goldenberg DM. (2007) Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.. Oncogene, 26 (25): (3704-13). [PMID:17530024] [10.1021/op500134e] |
| 4. Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM. (2007) Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.. Mol Immunol, 44 (6): (1331-41). [PMID:16814387] [10.1021/op500134e] |
| 5. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C et al.. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.. Blood, 103 (5): (1807-14). [PMID:14615373] [10.1021/op500134e] |
| 6. Abdu-Allah HH, Watanabe K, Completo GC, Sadagopan M, Hayashizaki K, Takaku C, Tamanaka T, Takematsu H, Kozutsumi Y, Paulson JC, Tsubata T, Ando H, Ishida H, Kiso M.. (2011) CD22-antagonists with nanomolar potency: the synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold.. Bioorg Med Chem, 19 (6): (1966-1971). [PMID:21349726] [10.1016/j.bmc.2011.01.060] |
| 7. Abdu-Allah HHM,Wu SC,Lin CH,Tseng YY. (2020) Design, synthesis and molecular docking study of α-triazolylsialosides as non-hydrolyzable and potent CD22 ligands.. Eur J Med Chem, 208 (112707-112707). [PMID:32942185] [10.1016/j.ejmech.2020.112707] |
| 8. Stamenkovic, I I and Seed, B B.. (1990) The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion.. Nature, (3): [PMID:1691828] |
| 9. Wilson, G L GL, Fox, C H CH, Fauci, A S AS and Kehrl, J H JH.. (1991) cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions.. The Journal of experimental medicine, (1): [PMID:1985119] |
| 10. Doody, G M GM and 6 more authors.. (1995) A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP.. Science (New York, N.Y.), (14): [PMID:7618087] |
| 11. Powell, L D LD, Sgroi, D D, Sjoberg, E R ER, Stamenkovic, I I and Varki, A A.. (1993) Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition.. The Journal of biological chemistry, (5): [PMID:8463235] |
| 12. Wilson, G L GL and 5 more authors.. (1993) Genomic structure and chromosomal mapping of the human CD22 gene.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:8496602] |
| 13. Law, C L CL and 6 more authors.. (1996) CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation.. The Journal of experimental medicine, (1): [PMID:8627166] |
| 14. Tuscano, J M JM, Engel, P P, Tedder, T F TF, Agarwal, A A and Kehrl, J H JH.. (1996) Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22.. European journal of immunology, [PMID:8647200] |
| 15. Tedder, T F TF, Tuscano, J J, Sato, S S and Kehrl, J H JH.. (1997) CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.. Annual review of immunology, [PMID:9143697] |
| 16. Hatta, Y Y and 5 more authors.. (1999) Identification of the gene variations in human CD22.. Immunogenetics, [PMID:10079291] |
| 17. Steinfeld, Serge D SD and Youinou, Pierre P.. (2006) Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.. Expert opinion on biological therapy, [PMID:16918261] |
| 18. Thota, Swapna S and Advani, Anjali A.. (2017) Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.. European journal of haematology, [PMID:28152223] |
首页
400-620-6333
